Study S001968

Efficacy and Safety of NNC0487-0111 s.c. Once-weekly Compared to Semaglutide s.c. Once-weekly in Participants With Overweight or Obesity, and Type 2 Diabetes (AMAZE 8)

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07400107
Acronym: AMAZE 8
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: NOT_YET_RECRUITING
Enrollment: 1000
Start: 2026-05-20
Primary completion: 2028-12-12
Lead sponsor: Novo Nordisk A/S
Conditions: Obesity; Overweight; Diabetes Mellitus, Type 2
Interventions: DRUG:NNC0487-0111; DRUG:Semaglutide; DRUG:Placebo (matched to NNC0487-0111); DRUG:Placebo (matched to semaglutide)
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1313-8017; OTHER:2024-520446-31

Registered primary outcomes

Relative change in body weight [From baseline (week 0) to week 84]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.